Register entry
SEAGEN INC.
- Registered sites
- 0
- Drug products
- 6
- Live patents
- 14
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
14Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| TUKYSA | TUCATINIB | May 2027 |
| TUKYSA | TUCATINIB | Oct 2032 |
| TUKYSA | TUCATINIB | Mar 2033 |
| TUKYSA | TUCATINIB | Apr 2034 |
| TUKYSA | TUCATINIB | Apr 2038 |
Catalogue
Marketed products
6Showing 6 of 6.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| ADCETRIS | brentuximab vedotin | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | BLA |
| PADCEV EJFV | ENFORTUMAB VEDOTIN | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | BLA |
| PADCEV EJFV | ENFORTUMAB VEDOTIN | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | BLA |
| TIVDAK | tisotumab vedotin | INJECTION, POWDER, FOR SOLUTION | BLA |
| TUKYSA | tucatinib | TABLET | NDA |
| TUKYSA | tucatinib | TABLET | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.